Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Luspatercept in β-thalassemia: Meta-analysis of efficacy and safety across transfusion-dependent and non-transfusion-dependent populations

View Full Paper
Ask AI
Bookmark
Share

Authors

RNRithish NimmagaddaTVTejaswi VenigallaVCVenkateswarlu Chintagumpala

Discussion

Loading...

Member takes

Overview

Meta-analysis reveals luspatercept improves hemoglobin levels and reduces transfusion needs in β-thalassemia, suggesting its efficacy and safety.

Key Points

  • Luspatercept significantly reduces transfusion burden in transfusion-dependent β-thalassemia.
  • Pooled data indicates 74% achieved ≥33% reduction in transfusion needs across trials.
  • Analysis of prospective trials provided insights into efficacy and safety outcomes in β-thalassemia.
  • Findings support luspatercept as a transformative therapy, though moderate bias limits evidence certainty.

Cite This Study

Nimmagadda et al. (2025) studied this question.

synapsesocial.com/papers/69362f7d4fa91c937236e479https://doi.org/10.1182/blood-2025-1145
View Full Paper
Ask AI
Bookmark
Share